RedHill Biopharma recent Real Value cannot be determined due to lack of data. The prevailing price of RedHill Biopharma is S312.0. Based on Macroaxis valuation methodology, the company cannot be evaluated at this time. Macroaxis determines value of RedHill Biopharma from analyzing the company fundamentals such as Return On Equity of
(80.66)%, Price to Sales of 105.87X and Current Valuation of 831.92M as well as examining its technical indicators and Probability Of Bankruptcy. In general, we support investing in undervalued entities and to dispose of overvalued entities since at some point stocks prices and their ongoing real values will merge together.
April 20, 2019
RedHill Biopharma is Unknown risk asset. Calculation of real value of RedHill Biopharma is based on 2 months time horizon. Increasing RedHill Biopharma time horizon generally increases accuracy of value calculation and significantly improves predictive power of the methodology used.
|Horizon||30 Days Login to change|
RedHill Biopharma Ltd is rated third in price to sales category among related companies. It is rated below average in beta category among related companies totaling about 0.01 of Beta per Price to Sales. The ratio of Price to Sales to Beta for RedHill Biopharma Ltd is roughly 155.69
|Price to Sales ( times )|